Scholarlink

<p>Exosomal proteins and miRNAs, including <i>α-synuclein</i>, <i>Aβ</i>, <i>tau</i>, <i>CXCL12, miR-24</i>, and <i>miR-23b-3p</i>, are emerging as valuable biomarkers for Parkinson’s disease and prenatal diagnostics, with significant potential for personalized therapies. Advances in MRI and chitosan-based drug delivery systems are creating new opportunities for diagnosing and treating neurodegenerative disorders. Exosomes regulate miRNAs and proteins, presenting theranostic potential for Alzheimer’s and Huntington’s diseases, yet facing delivery and targeting challenges. Exosomal miRNAs, such as <i>miR-1234</i>, <i>miR-5678</i>, and <i>miR-29a</i>, are crucial for the early detection and monitoring of the progression of neurodegenerative diseases. Additionally, novel biomarkers such as <i>SCA27B</i> and <i>FGF14</i> gene mutations and serum <i>miR-455–3p</i> offer promising noninvasive diagnostic methods for Alzheimer’s disease. The expanding role of exosome-derived miRNAs in targeting oncogenes and regulating the cell cycle enhances therapeutic strategies for neurological disorders, opening doors to more personalized and effective disease management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders

  • 期刊论文

  • 发表日期：

    2025年2月7日

查看全文
  • Azhagu Madhavan Sivalingam,
  • Darshitha D. Sureshkumar

摘要

Exosomal proteins and miRNAs, including α-synuclein, Aβ, tau, CXCL12, miR-24, and miR-23b-3p, are emerging as valuable biomarkers for Parkinson’s disease and prenatal diagnostics, with significant potential for personalized therapies. Advances in MRI and chitosan-based drug delivery systems are creating new opportunities for diagnosing and treating neurodegenerative disorders. Exosomes regulate miRNAs and proteins, presenting theranostic potential for Alzheimer’s and Huntington’s diseases, yet facing delivery and targeting challenges. Exosomal miRNAs, such as miR-1234, miR-5678, and miR-29a, are crucial for the early detection and monitoring of the progression of neurodegenerative diseases. Additionally, novel biomarkers such as SCA27B and FGF14 gene mutations and serum miR-455–3p offer promising noninvasive diagnostic methods for Alzheimer’s disease. The expanding role of exosome-derived miRNAs in targeting oncogenes and regulating the cell cycle enhances therapeutic strategies for neurological disorders, opening doors to more personalized and effective disease management.